In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving ...
Pharmaceutical Executive: What AI trends did you see at the 2026 JP Morgan Healthcare Conference? Angela Schwab: Good and bad. You see a lot of players coming into the market saying that they can do ...
When you can’t find specialized talent in the usual places, it undermines timelines for R&D, clinical trials, and commercialization. But there are other locations that employers can explore when ...
AstraZeneca entered a strategic collaboration with CSPC Pharmaceuticals to expand its weight management and metabolic disease ...
The deal underscores a broader shift in autoimmune drug development toward therapies that aim to reprogram disease-driving ...
The real “commercial launch” happens years before launch preparation officially begins. Once Phase III begins, your evidence ...
Teva's Honestly HD campaign, featuring Will Forte, aims to raise awareness about Huntington's disease through personal ...
In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still ...
The US Department of Health and Human Services (HHS) issued new guidance clarifying how pharmaceutical manufacturers can ...
Public Citizen filed a lawsuit against the Trump administration in the U.S. District Court for the District of Columbia ...
Tenpoint Therapeutics announced FDA’s approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% ...
PE: After presenting topline results from Phase 3 trials, what's next for Varegacestat? Siegall: We presented topline data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results